VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

iwNHL 2017 | Overcoming toxicities when combining PI3K inhibitors with other treatments

Idelalisib was the first phosphoinositide 3-kinase (PI3K) inhibitor to be used in lymphoma, which had remarkable responses on B-cell lymphomas as a single-agent. Nathan Fowler, MD at the University of Texas MD Anderson Cancer Center, Houston, TX talks about the different combination studies with idelalisib, and how we are trying to overcome toxicities found, by developing second-generation PI3K inhibitors, such as copanlisib, umbralisib, and duvelisib.
Recorded at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017 annual meeting, held in Vancouver, BC, Canada.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter